Advancement to Clinical Candidate of Novel, Potent and Selective Chikungunya virus inhibitor series

DESCRIPTIONprovided by applicantNovel therapies for the treatment of Chikungunya virusCHIKVinfections are urgently needed to address the alarming spread of this pathogen across the AmericasWe have identified a series of potentselectiveand orally bioavailable inhibitors of CHIKV replicationIn this Direct to Phaseprojectwe will optimize this series of CHIKV inhibitors to Pre Development stage and advance a first ever CHIKV antiviral candidate to IND enabling studiesTo accomplish this taskwe will execute an integrated medicinal chemistry optimization biological profiling campaign to optimize the potencydrug like properties and oral exposure of the seriesOne or more Pre Development Candidates will be identified and advanced through candidate selection studies into non GLP repeat dose tox in both rats and dogs